Abbott Laboratories (ABT) released its fourth-quarter 2020 results on Wednesday, January 27, before trading opened. Sales growth exceeded Wall Street expectations in the diagnostics segment. Additionally, Abbott Laboratories claims to be a dividend aristocrat after the next dividend increase.
Abbot Laboratories reported an increase in revenue of 29% in the fourth quarter of 2020 to $10.7 billion. In this period, the net income was 2.2 billion dollars or $1.2 per share. More specifically, this is more than double the amount for the same quarter a year ago. Earnings per share increased 53% year over year to $1.45 per share.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Abbott Laboratories (ABT) has experienced growth in the diagnostic products segment in recent years, particularly in tests for COVID-19. The company reported global sales of $2.4 billion in the quarter related to COVID-19 testing. Abbott Laboratories diagnostics segment revenue increased by 111% to $4.3 billion from the previous year. Pharma sales generally decreased by 2.3% YoY, but its overall success looked more modest. In the same period, the company’s revenues increased by 41% in the diabetic goods segment. Glucose management sales grew more than 40% to $917 million thanks to the FreeStyleLibre continuous glucose monitoring system’s growth.
Abbott Laboratories anticipates an increase in earnings per share of over 35% in 2021 to about $5. Abbott Laboratories also calls itself a dividend aristocrat – a term used to describe a company that has been raising dividends consistently for at least 50 years. Abbott Laboratories increased its payout by 25% last year. As a result, if the company can significantly increase payments, it can become a dividend aristocrat.
The relationship between Abbott Laboratories (ABT) 200-day and 20-day major moving averages indicates that the company is rally. ABT shares have grown 8.82% in the past 30 days. Over the past 12 months, the stock has gained 35.06%.